Plus Therapeutics, a clinical-stage pharmaceutical company, announced positive interim updates from its ReSPECT™ clinical trials at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting. The ReSPECT-GBM Phase 1 trial showed safety and overall survival correlation with absorbed radiation dose in recurrent glioblastoma patients. The ReSPECT-LM Phase 1/Part A trial demonstrated safety and high absorbed radiation doses to treat leptomeningeal metastases.
The interim results from the ReSPECT-GBM trial included data from 21 patients in the Phase 1 trial, supporting the recommended Phase 2 trial dose for patients with tumor volumes ≤20 mL. The treatment with rhenium (186Re) obisbemeda was safe and well-tolerated, showing efficacy signals in an unfavorable patient population. The median overall survival for all 21 patients was 11 months, a significant increase compared to standard care.
In the ReSPECT